ECB's Villeroy: Volatility reflects trade wars, not currency wars
PARIS: European Central Bank policymaker Francois Villeroy de Galhau said economic and market volatility reflected trade wars rather than currency wars.
'Unfortunately, there is a risk of trade war, but a currency war would be a situation where each country is actively using its interest rates to try and gain an economic advantage. We are not at that point right now,' Villeroy, who also heads the Bank of France, told regional French newspapers in an interview published on Friday.
ECB to stand by past stimulus policies in strategy review
'The current currency moves are more of a reflection on revisions to economic forecasts,' added Villeroy, who is also head of the Bank of France.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
9 hours ago
- Business Recorder
Dollar holds near six-week low as trade war wears on US economy
TOKYO: The dollar touched a six-week low on Tuesday on signs of fragility in the U.S. economy because of damage from the trade war President Donald Trump's administration is waging. While global equity markets have broadly recovered in the wake of the on-again, off-again saga of Trump's tariff threats, the greenback remains firmly on its back. Factory and jobs data in the United States in the coming days may give further signs of the toll that trade uncertainty is wreaking on the world's biggest economy. U.S. duties on imported steel and aluminum are set to double to 50% starting on Wednesday, the same day the Trump administration expects countries to submit their best offers in trade negotiations. 'What this whole dynamic is basically saying is trade tensions are not really improving in that regard, and we've seen the dollar getting hammered widely,' said Rodrigo Catril, senior FX strategist at National Australia Bank. 'Interestingly, the Aussie and the kiwi have been the good performers this time around.' The dollar index, which measures the U.S. currency against six major peers, touched 98.58, the lowest since late April, before rebounding 0.3%. The greenback rallied 0.3% to 143.21 yen. Weak dollar reprises its role as 'carry' trade funder The euro slid 0.2% after briefly touching a six-week high of $1.1454. Later in the week, the focus will be on the European Central Bank's interest rate decision and subsequent outlook. New Zealand's kiwi reached $0.6054, a new high for the year, before retreating 0.4%. The dollar index sank 0.8% on Monday after data showed U.S. manufacturing contracted for a third month in May and tariff snarls meant suppliers took longer to deliver goods. Attention now turns to U.S. factory order numbers on Tuesday, along with jobs figures due later in the week. The dollar got some respite last week, rising 0.3% after trade talks with the European Union got back on track and a U.S. trade court blocked the bulk of Trump's tariffs. An appeals court reinstated the duties a day later, and Trump's administration said it had other avenues to implement them if it loses in court. Trump and Chinese President Xi Jinping were likely to have a call soon to iron out trade differences, Treasury Secretary Scott Bessent said on Sunday, although Monday saw an angry rejection from China's Commerce Ministry of U.S. accusations that Beijing violated their trade agreement. Fiscal worries have also given rise to a broad 'sell America' theme that has seen dollar assets from stocks to Treasury bonds dropping in recent months. Those concerns come into sharp focus this week as the Senate starts considering the administration's tax cut and spending bill, estimated to add $3.8 trillion to the federal government's $36.2 trillion in debt over the next decade.
Express Tribune
a day ago
- Express Tribune
Sanofi's $9.5B acquisition of Blueprint Medicines strengthens rare immunology portfolio
In a major move underscoring its ambition to lead in rare diseases and immunology, French pharmaceutical giant Sanofi announced its plan to acquire US-based Blueprint Medicines for up to $9.5 billion. The deal was announced by a press release on Sanofi's website. It is the largest by a European healthcare company this year and will see Sanofi paying $129 per share in cash, a significant premium that sent Blueprint's stock soaring in premarket trading. Blueprint Medicines, known for its specialty in treating systemic mastocytosis a rare blood disorder marked by the overproduction of mast cells brings to Sanofi a strong foothold in a niche yet critical area of medicine. The acquisition adds the FDA-approved drug Ayvakit, the only treatment for advanced systemic mastocytosis, to Sanofi's growing immunology portfolio. Sanofi CEO Paul Hudson framed the deal as a strategic leap forward, enhancing the company's pipeline and reinforcing its transformation into a global leader in immunology. We announced an agreement to acquire Blueprint Medicines, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases. — Sanofi (@sanofi) June 2, 2025 With a promising pipeline including next-generation therapies like elenestinib and BLU-808, the acquisition fits into Sanofi's broader ambition of innovation despite recent setbacks, including a failed lung disease drug trial. Industry analysts from JP Morgan praised the acquisition for its strategic and financial merits, forecasting Ayvakit could generate $2 billion in annual sales by 2030. Sanofi's ongoing spree of acquisitions, including Vigil Neuroscience and Inhibrx, signals a company doubling down on R&D investments to reshape its future. The acquisition aligns with Sanofi's broader strategy to invest heavily in US manufacturing and research, tapping into incentives and momentum driven by recent government policies. With Blueprint Medicines now joining its portfolio, Sanofi cements its stake in cutting-edge immunology treatments and rare disease therapies, positioning itself for long-term growth in a competitive pharmaceutical landscape.
Business Recorder
a day ago
- Business Recorder
European shares start lower after Trump's fresh tariff threats
European shares opened lower on Monday, after rounding off monthly gains in May, as U.S. President Donald Trump's new tariff plans threatened to rekindle global trade tensions. The continent-wide STOXX 600 was down 0.2% as of 0708 GMT. Late on Friday, Trump said he planned to increase tariffs on imported steel and aluminum to 50% from 25%, to which the European Union said it was prepared to retaliate. Steel companies in Europe fell, with ArcelorMittal down 1% and conglomerate Thyssenkrupp down 1.1%. The tariffs, which can impact automobiles, weighed on stocks of carmakers, with the sector down 1.2%. European shares end May higher as trade uncertainty persists Meanwhile, Sanofi agreed to buy U.S.-based Blueprint Medicines Corporation paying $129 per share, representing an equity value of approximately $9.1 billion. Shares in the French pharma group were slightly lower. This week, the spotlight will be on the European Central Bank, which will announce its interest rate decision on Thursday. Comments from Federal Reserve Chair Jerome Powell and ECB President Christine Lagarde will be on tap, alongside a slew of economic data out of the trade bloc.
